GENT: Strong Q3 growth driven by U.S. sales and Cystatin C, with robust margins and advancing R&D

About this update from Gentian Diagnostics Asa

Q3 2025 saw strong revenue and EBITDA growth, led by U.S. expansion and Cystatin C adoption. Gross margin recovered, and R&D advanced NT-proBNP and other projects. Cautious outlook for China, but U.S. momentum expected to continue.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Gentian Diagnostics Asa